Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components
Fedosyuk S. et al, (2019), Vaccine, 37, 6951 - 6961
Rift Valley fever: biology and epidemiology
Wright D. et al, (2019), Journal of General Virology, 100, 1187 - 1199
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
Venkatraman N. et al, (2019), The Journal of Infectious Diseases, 219, 1187 - 1197
Association between Rift Valley fever virus seroprevalences in livestock and humans and their respective intra-cluster correlation coefficients, Tana River County, Kenya
Bett B. et al, (2019), Epidemiology and Infection, 147
A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus
Allen ER. et al, (2018), Cell Reports, 25, 3750 - 3758.e4
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
Rampling T. et al, (2018), npj Vaccines, 3
Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
O’Shea MK. et al, (2018), Scientific Reports, 8
Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials
Bowyer G. et al, (2018), Vaccines, 6, 50 - 50
CHARACTERIZING THE IMMUNE RESPONSE TO RIFT VALLEY FEVER VIRUS IN MULTIPLE SPECIES AFTER NATURAL EXPOSURE OR VACCINATION WITH CHADOX1-RVF
Wright D. et al, (2018), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 99, 424 - 424
Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model
Munster VJ. et al, (2017), npj Vaccines, 2
Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™
Venkatraman N. et al, (2017), Vaccine, 35, 6208 - 6217
IDENTIFICATION OF HUMAN T CELL EPITOPES IN THE EBOLAVIRUS GLYCOPROTEIN FOLLOWING VACCINATION WITH CHAD3 EBO Z GP AND MVA BN
Wright D. et al, (2017), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 95, 412 - 412
Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
Mensah VA. et al, (2016), PLOS ONE, 11, e0167951 - e0167951
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
Ewer K. et al, (2016), New England Journal of Medicine, 374, 1635 - 1646
Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle
Dulal P. et al, (2016), Vaccine, 34, 2296 - 2298
Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever
Warimwe GM. et al, (2016), Scientific Reports, 6
Safety and immunogenicity of the heterologous prime-boost Ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN® FILO in healthy UK adults
Rampling T. et al, (2015), Journal of Infection, 71, 688 - 688
BOOSTING THE NOVEL EBOLA VACCINE CANDIDATE CHADEBOV Z WITH MODIFIED VACCINIA VIRUS ANKARA (MVA) SIGNIFICANTLY ENHANCES EBOLA-SPECIFIC ANTIBODY RESPONSES
Bowyer G. et al, (2015), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93, 54 - 54
IMPACT ON IMMUNOGENICITY OF VARYING THE INTERVAL BETWEEN THE PRIME AND BOOST OF A CANDIDATE EBOLA VACCINE CHAD3-EBO Z AND MVA-BN FILO IN HEALTHY UK ADULTS
Wright D. et al, (2015), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93, 54 - 55
SAFETY AND IMMUNOGENICITY OF THE HETEROLOGOUS PRIME-BOOST EBOLAVIRUS VACCINE REGIMEN CHAD3-EBO Z AND MVA-BN® FILO IN HEALTHY UK ADULTS
Rampling T. et al, (2015), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93, 446 - 447
SAFETY, IMMUNOGENICITY AND EFFICACY OF THE COMBINATION MALARIA VACCINE REGIMEN OF RTS, S/AS01B CONCOMITANTLY ADMINISTERED WITH CHAD-MVA VIRAL VECTORS EXPRESSING ME-TRAP
Rampling T. et al, (2015), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93, 391 - 391